AMENDMENT TO THE CLAIMS

1-51. (Canceled)

52. (Currently amended) A composition, for delivery of a therapeutic agent to a neuronal cell, comprising:

a therapeutic agent which inhibits at least one member of the Rho group of GTPases.

a neuronal cell targeting component, which component comprises a Hc domain of botulinum C1 toxin, or a fragment thereof which retains the function of the native Hc domain, and

a domain for translocation of the therapeutic agent into a cell, wherein the Hc domain has been made recombinantly, and the therapeutic agent is an ADP-ribosyltransferase, and the therapeutic agent is selected from the group consisting of:

a C3 enzyme having an amino acid sequence selected from the group consisting of SEQ ID Nos: 1-10, and

<u>a C3 enzyme selected from the group consisting of S. aureus C3</u> <u>exoenzyme 1 isoform, S. aureus C3 exoenzyme 2 isoform and C. botulinum C3</u> <u>exoenzyme</u>.

- 53. (Previously Presented) A composition according to Claim 52, wherein the translocation domain is derived from a clostridial source.
- 54. (Withdrawn Previously Presented) A composition according to Claim 52, wherein the translocation domain is derived from a non-clostridial source.

- 55. (Previously Presented) A composition according to Claim 53, wherein the translocation domain is derived from *C. botulinum, C. butylicum, C. argentinense* or *C. tetani*.
- 56. (Withdrawn Previously Presented) A composition according to Claim 54, wherein the translocation domain comprises a translocation domain of diphtheria toxin, Pseudomonas exotoxin A, influenza virus haemagglutinin fusogenic peptides or amphiphilic peptides.
- 57. (Previously Presented) A composition according to Claim 52, wherein the translocation domain comprises a member selected from the group consisting of botulinum C1 toxin and fragments thereof, and diphtheria toxin and fragments thereof.
- 58. (Previously Presented) A composition according to Claim 52, wherein the translocation domain is a membrane disrupting peptide.
- 59-63. (Cancelled)
- 64. (Previously Presented) A composition according to Claim 52, wherein the therapeutic agent and the Hc domain are joined to each other directly or via a linker molecule.
- 65. (Previously Presented) A composition according to Claim 52, wherein the therapeutic agent, the Hc domain and the translocation domain are joined to each other directly or via a linker molecule.
- 66. (Previously Presented) A composition according to Claim 64, wherein the linker molecule is selected from the group consisting of the interdomain linker of cellulase,

collagen spacer, trypsin-sensitive diphtheria toxin peptide, and linker molecules having an amino acid sequence of SEQ ID Nos: 16-27.

- 67. (Previously Presented) A composition according to Claim 65, wherein the linker molecule is selected from the group consisting of the interdomain linker of cellulase, collagen spacer, trypsin-sensitive diphtheria toxin peptide, and linker molecules having an amino acid sequence of SEQ ID Nos: 16-27.
- 68. (Previously Presented) A composition according to Claim 52, wherein the composition is a single polypeptide.
- 69. (Previously Presented) A composition according to Claim 52, wherein the composition is a dichain polypeptide.
- 70. (Previously Presented) A composition according to Claim 52, wherein the composition is a suspension, emulsion, solution or a freeze-dried powder.
- 71. (Previously Presented) A composition according to Claim 52, further comprising a pharmaceutically acceptable liquid.
- 72. (Withdrawn Previously Presented) A method of making a composition according to Claim 52, comprising expressing a DNA encoding the therapeutic agent and the neuronal cell targeting domain.
- 73. (New) A composition according to Claim 53, wherein the therapeutic agent and the Hc domain are joined to each other directly or via a linker molecule.
- 74. (New) A composition according to Claim 53, wherein the therapeutic agent, the Hc domain and the translocation domain are joined to each other directly or via a linker molecule.

- 75. (New) A composition according to Claim 53, wherein the composition is a single polypeptide.
- 76. (New) A composition according to Claim 53, wherein the composition is a dichain polypeptide.
- 77. (New) A composition according to Claim 53, wherein the composition is a suspension, emulsion, solution or a freeze-dried powder.
- 78. (New) A composition according to Claim 53, further comprising a pharmaceutically acceptable liquid.